Compare Illumina, Inc. (ILMN) vs Financial Select Sector SPDR Fund (XLF) Price & Performance

Illumina, Inc.Trade

Financial Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs Financial Select Sector SPDR Fund — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Financial Select Sector SPDR Fund trades at $55.94. Which is the better fit depends on your goals.

	ILMN	XLF
Market Cap	$27.94B	—
Sector	Health	—
52-Week High	$194.33	$56.75
52-Week Low	$91.00	$47.80
Enterprise Value	$29.33B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.

Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.

Financial Select Sector SPDR Fund

XLF trades at $56.04, down 0.39% on the day, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF benefits from strong bank earnings and dividend increases following Fed stress tests. Recent news highlights regional bank strength and AI-driven capital markets activity as key growth drivers.

Outlook remains positive due to robust financial sector performance and potential Fed rate hikes, though geopolitical risks and overbought conditions pose near-term headwinds. The ETF offers exposure to banking sector resilience with a low expense ratio of 0.08%.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ILMN

Cancer biomarkers market to hit $54.48B by 2032, driven by tech advances and Asia-Pacific growthResearchandmarkets.Com · 4 days agoBullish New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral Illumina's Billion Cell Atlas adds Formation Bio to boost AI-driven drug discovery with massive genomic data.PRNewsWire · 4 days agoBullish View details →

XLF

John Hancock Financial Opportunities Fund offers 6.5% growing dividend, beating S&P 500 and financial ETFs.Forbes · 4 hours agoBullish View details →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

About Financial Select Sector SPDR Fund

The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.